*May 2021*

The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation after progression on an EGFR tyrosine kinase inhibitor (TKI), according to results from a phase 1B/2 study presented in a poster during the American Association for Cancer Research Annual Meeting 2021. Read more.

Donate

Support EGFR

Latest Newsletter

Get Social: Twitter

Categories